Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

News provided by

Jan 29, 2015, 07:00 ET

WASHINGTON, Jan. 29, 2015 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders, today announced that members of its management team will participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day on Tuesday, February 3, 2015 in New York, NY.

For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com.

Investor Contact:
Jim Kelly
Senior Vice President and Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
[email protected]

SOURCE Vanda Pharmaceuticals Inc.